Pfizer (PFE) Given a $39.00 Price Target at BMO Capital Markets

BMO Capital Markets set a $39.00 price target on Pfizer (NYSE:PFE) in a research note issued to investors on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Friday, January 5th. Nord/LB reiterated a neutral rating on shares of Pfizer in a research note on Tuesday, January 2nd. UBS Group set a $40.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, December 6th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, December 6th. Finally, Vetr upgraded shares of Pfizer from a hold rating to a buy rating and set a $38.82 price objective for the company in a research note on Thursday, November 23rd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. Pfizer presently has an average rating of Buy and an average target price of $38.83.

Pfizer (NYSE PFE) traded up $0.09 on Monday, hitting $36.56. 11,010,000 shares of the company were exchanged, compared to its average volume of 15,770,000. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer has a 12 month low of $30.90 and a 12 month high of $37.35. The firm has a market cap of $217,920.00, a price-to-earnings ratio of 22.43, a PEG ratio of 2.46 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 EPS. sell-side analysts predict that Pfizer will post 2.59 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

Pfizer declared that its board has approved a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,450 shares of company stock valued at $1,065,220. 0.06% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. purchased a new position in Pfizer in the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer in the 2nd quarter worth $103,000. D. Scott Neal Inc. raised its position in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC purchased a new position in Pfizer in the 2nd quarter worth $120,000. Finally, Americafirst Capital Management LLC purchased a new position in Pfizer in the 3rd quarter worth $127,000. 69.74% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2018/01/11/pfizer-pfe-given-a-39-00-price-target-at-bmo-capital-markets.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit